BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29678941)

  • 1. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer.
    Igusa T; Hummers LK; Visvanathan K; Richardson C; Wigley FM; Casciola-Rosen L; Rosen A; Shah AA
    Ann Rheum Dis; 2018 Aug; 77(8):1179-1186. PubMed ID: 29678941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome.
    Graf SW; Hakendorf P; Lester S; Patterson K; Walker JG; Smith MD; Ahern MJ; Roberts-Thomson PJ
    Int J Rheum Dis; 2012 Feb; 15(1):102-9. PubMed ID: 22324953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of cancer in patients with scleroderma: a population based cohort study.
    Hill CL; Nguyen AM; Roder D; Roberts-Thomson P
    Ann Rheum Dis; 2003 Aug; 62(8):728-31. PubMed ID: 12860727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course.
    Kim JS; Woods A; Gutierrez-Alamillo L; Laffoon M; Wigley FM; Hummers LK; Rosen A; Zeger S; Domsic RT; Casciola-Rosen L; Shah AA
    Arthritis Rheumatol; 2024 Jan; 76(1):68-77. PubMed ID: 37488962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection.
    Shah AA; Igusa T; Goldman D; Li J; Casciola-Rosen L; Rosen A; Petri M
    Arthritis Res Ther; 2021 Feb; 23(1):64. PubMed ID: 33632283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma.
    Shah AA; Xu G; Rosen A; Hummers LK; Wigley FM; Elledge SJ; Casciola-Rosen L
    Arthritis Rheumatol; 2017 Jun; 69(6):1306-1312. PubMed ID: 28217959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.
    Gelber AC; Manno RL; Shah AA; Woods A; Le EN; Boin F; Hummers LK; Wigley FM
    Medicine (Baltimore); 2013 Jul; 92(4):191-205. PubMed ID: 23793108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais.
    Foocharoen C; Watcharenwong P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
    Int J Rheum Dis; 2017 Oct; 20(10):1572-1581. PubMed ID: 28296274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.
    Shah AA; Rosen A; Hummers L; Wigley F; Casciola-Rosen L
    Arthritis Rheum; 2010 Sep; 62(9):2787-95. PubMed ID: 20506513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE).
    Carbonell C; Marcos M; Guillén-Del-Castillo A; Rubio-Rivas M; Argibay A; Marín-Ballvé A; Rodríguez-Pintó I; Baldà-Masmiquel M; Callejas-Moraga E; Colunga D; Sáez-Comet L; González-Echávarri C; Ortego-Centeno N; Marí-Alfonso B; Vargas-Hitos JA; Todolí-Parra JA; Trapiella L; Herranz-Marín MT; Freire M; Castro-Salomó A; Perales-Fraile I; Madroñero-Vuelta AB; Sánchez-García ME; Ruiz-Muñoz M; González-García A; Sánchez-Redondo J; de-la-Red-Bellvis G; Fernández-Luque A; Muela-Molinero A; Lledó GM; Tolosa-Vilella C; Fonollosa-Pla V; Chamorro AJ; Simeón-Aznar CP;
    Autoimmun Rev; 2022 Oct; 21(10):103167. PubMed ID: 35931315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
    Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
    Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex.
    Mecoli CA; Adler BL; Yang Q; Hummers LK; Rosen A; Casciola-Rosen L; Shah AA
    Arthritis Rheumatol; 2021 Feb; 73(2):315-323. PubMed ID: 33241644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry.
    Hinchcliff M; Khanna S; Hsu VM; Lee J; Almagor O; Chang RW; Steen V; Chung L;
    Semin Arthritis Rheum; 2015 Dec; 45(3):309-14. PubMed ID: 26210782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Fc gamma receptor-specific autoantibodies in localized and systemic scleroderma.
    Davis K; Boros P; Keltz M; Unkeless JC; Fleischmajer R
    J Am Acad Dermatol; 1995 Oct; 33(4):612-6. PubMed ID: 7673494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between autoantibodies in systemic sclerosis and cancer in a national registry.
    Hoa S; Lazizi S; Baron M; Wang M; Fritzler MJ; Hudson M;
    Rheumatology (Oxford); 2022 Jul; 61(7):2905-2914. PubMed ID: 34599801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease.
    Shah AA; Rosen A; Hummers LK; May BJ; Kaushiva A; Roden RBS; Armstrong DK; Wigley FM; Casciola-Rosen L; Visvanathan K
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):71-74. PubMed ID: 28628466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.
    Shah AA; Hummers LK; Casciola-Rosen L; Visvanathan K; Rosen A; Wigley FM
    Arthritis Rheumatol; 2015 Apr; 67(4):1053-61. PubMed ID: 25605296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
    Walker UA; Tyndall A; Czirják L; Denton C; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Bocelli-Tyndall C; Matucci-Cerinic M
    Ann Rheum Dis; 2007 Jun; 66(6):754-63. PubMed ID: 17234652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of cancer among patients with systemic sclerosis.
    Rosenthal AK; McLaughlin JK; Gridley G; Nyrén O
    Cancer; 1995 Sep; 76(5):910-4. PubMed ID: 8625197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis.
    Terras S; Hartenstein H; Höxtermann S; Gambichler T; Kreuter A
    Int J Dermatol; 2016 Aug; 55(8):882-5. PubMed ID: 26499848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.